On 10 Dec 2023, the 3-Year final analysis of efficacy and safety of Ruxolitinib from the phase III REACH3 study will be unveiled at the 2023 ASH Congress.

Origen Chengdu and Vanotech have declared the first patient has received their gene therapy in the Phase 1 trial of VAN-2201 for Wet Macular Degeneration associated with aging.

IRAK4 inhibitors: Pioneering immune response regulation and promising future in combating hematologic malignancies.

At the 2023 SNO Annual Conference, Imvax displayed novel findings advocating for its principal project, IGV-001, targeting recently identified Glioblastoma.

On 11 Dec 2023, the updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2) in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) will be reported in 2023 ASH.

HOOKIPA Pharma Inc. has officially disclosed that the FDA has given the clearance for its IND application for HB-500, This is a new arenaviral therapeutic vaccine designed for HIV treatment.

JAK2 inhibitors: Revolutionizing treatments for hematological disorders with a promising future.

Sandoz announces the launch of its citrate-free high concentration Hyrimoz® (adalimumab) in Europe, with availability starting today in various countries.

On 11 Dec 2023, The clinical data about Axicabtagene Ciloleucel from pivotal ZUMA-7 study will be updated in 2023 ASH.

European Commission gives the green light to Ascendis Pharma's YORVIPATH® (palopegteriparatide) for managing chronic Hypoparathyroidism in adults.

The KRAS mutation, as a significant driving factor for non-small cell lung cancer, has long been a challenging type of mutation. However, the recent development and clinical application of various KRAS inhibitors have brought us new hope.

ProMIS Neurosciences initiates Phase 1a clinical trial, injecting the first participants with PMN310, a potential Alzheimer’s Disease treatment.